Pertuzumab (P) in combination with trastuzumab (T) and docetaxel (D) in elderly patients with HER2-positive metastatic breast cancer in the CLEOPATRA study

被引：0
|
作者：
Miles, D.
Baselga, J.
Amadori, D.
Sunpaweravong, P.
Semiglazov, V.
Knott, A.
Clark, E.
Ross, G.
Swain, S. M.
机构：
[1] Mt Vernon Canc Ctr, Northwood, Middx, England
[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, Italy
[5] Prince Songkla Univ, Songklanagarind Hosp, Hat Yai, Thailand
[6] NN Petrov Res Inst Oncol, St Petersburg, Russia
[7] Roche Prod Ltd, Welwyn Garden City, England
[8] MedStar Washington Hosp Ctr, Washington, DC USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-P5-18-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-18-01
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Dramatic CLEOPATRA Findings Support Addition of Pertuzumab to Regimen for HER2-Positive Metastatic Breast Cancer
    不详
    ONCOLOGY-NEW YORK, 2011, 25 (14): : 1416 - 1416
  • [32] Skin and subcutaneous tissue disorders (SSTDs) in patients (pts) with HER2-positive metastatic breast cancer (MBC) in the phase III trial CLEOPATRA of pertuzumab or placebo with trastuzumab and docetaxel.
    Miles, David
    Lacasia, Andrea
    Lee, Luen
    Dana, Kenneth
    Heeson, Sarah
    Knott, Adam
    Portera, Chia C.
    Swain, Sandra M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    Douchet, G.
    Richard, Sandrine
    ONCOLOGIE, 2018, 20 (01) : 43 - 44
  • [34] A cases of pertuzumab plus trastuzumab plus docetaxel was effective for inflammatory breast cancer with HER2-positive
    Yamashita, Yuji
    Tanaka, Yuko
    Nishimura, Meiko
    Mukohara, Toru
    Kono, Seishi
    Takao, Shintaro
    Minami, Hironobu
    ANNALS OF ONCOLOGY, 2015, 26 : 143 - 143
  • [35] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    von Minckwitz, Gunter
    Procter, Marion
    de Azambuja, Evandro
    Zardavas, Dimitrios
    Benyunes, Mark
    Viale, Giuseppe
    Suter, Thomas
    Arahmani, Amal
    Rouchet, Nathalie
    Clark, Emma
    Knott, Adam
    Lang, Istvan
    Levy, Christelle
    Yardley, Denise A.
    Bines, Jose
    Gelber, Richard D.
    Piccart, Martine
    Baselga, Jose
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 122 - 131
  • [36] Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer
    Paridaens, R., Sr.
    Wildiers, H.
    Dalenc, F.
    Rixe, O.
    Cadic, V.
    Pinel, M.
    Roche, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [37] Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study
    Luen, Stephen J.
    Salgado, Roberto
    Fox, Stephen
    Savas, Peter
    Eng-Wong, Jennifer
    Clark, Emma
    Kiermaier, Astrid
    Swain, Sandra M.
    Baselga, Jose
    Michiels, Stefan
    Loi, Sherene
    LANCET ONCOLOGY, 2017, 18 (01): : 52 - 62
  • [38] First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer
    Araki, Kazuhiro
    Fukada, Ippei
    Yanagi, Hiroyo
    Kobayashi, Kokoro
    Shibayama, Tomoko
    Horii, Rie
    Takahashi, Shunji
    Akiyama, Futoshi
    Ohno, Shinji
    Ito, Yoshinori
    BREAST, 2017, 35 : 78 - 84
  • [39] Pertuzumab (Perjeta) for HER2-Positive Metastatic Breast Cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2012, 54 (1395): : 59 - 60
  • [40] Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
    Al Rabadi, Luai S.
    Cook, Madeline M.
    Kaempf, Andy J.
    Saraceni, Megan M.
    Savin, Michael A.
    Mitri, Zahi, I
    BMC CANCER, 2021, 21 (01)
12345